Skip to main content
OpenTrials

Clinical trial condition

Recurrence

Explore clinical trials studying Recurrence. Study availability and eligibility vary by location and protocol.

2,308 public trials 520 recruiting studies
Refine in advanced search Browse all conditions

Recurrence trial results

Active, Not Recruiting

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

NCT05451810

Conditions
Classic Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Disease Attributes, +14 more
Locations
  • Infirmary Health - Infirmary Cancer Care at Mobile Infirmary /ID# 264630 Mobile, Alabama, United States
  • University of Arkansas for Medical Sciences /ID# 244562 Little Rock, Arkansas, United States
  • Highlands Oncology Group, PA /ID# 245002 Springdale, Arkansas, United States
  • Beverly Hills Cancer Center /ID# 255327 Beverly Hills, California, United States
View all 72 locations
View Trial Details
Active, Not Recruiting

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

NCT05578976

Conditions
Diffuse Large B-cell Lymphoma, Disease Attributes, Hemic and Lymphatic Diseases, +13 more
Locations
  • University of Arizona Cancer Center - North Campus /ID# 227463 Tucson, Arizona, United States
  • Yuma Regional Medical Center /ID# 261527 Yuma, Arizona, United States
  • University of Arkansas for Medical Sciences /ID# 225703 Little Rock, Arkansas, United States
  • CBCC Global Research, Inc. /ID# 262037 Bakersfield, California, United States
View all 331 locations
View Trial Details
Active, Not Recruiting

Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma

NCT05263583

Conditions
Burkitt Lymphoma, C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma, C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma, +24 more
Locations
  • Beijing Cancer Hospital Beijing, China
  • Sun Yat-sen University Cancer Center Guangzhou, China
  • Henan Cancer Hospital Henan, China
  • Shanghai East Hospital Pudong, China
View Trial Details
Active, Not Recruiting

A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)

NCT03634540

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +26 more
Locations
  • USC Norris Comprehensive Cancer Center ( Site 0060) Los Angeles, California, United States
  • Cedars Sinai Medical Center Samuel Oschin Comp. Cancer Institute ( Site 0003) Los Angeles, California, United States
  • Sylvester Comprehensive Cancer Center ( Site 0023) Miami, Florida, United States
  • Dana Farber Cancer Center ( Site 0006) Boston, Massachusetts, United States
View Trial Details
Active, Not Recruiting

RVU120 (SEL120) in Patients with Relapse/Refractory Metastatic or Advanced Solid Tumors

NCT05052255

Conditions
Advanced Solid Tumor, Disease Attributes, Neoplasm Metastasis, +5 more
Locations
  • Beskidzkie Centrum Onkologii, Szpital Miejski im. Bielsko-Biala, Poland
  • Medical University Early Phase 1 Research Center / Uniwersyteckie Centrum Kliniczne Ośrodek Badań Klinicznych Wczesnych Faz Gdansk, Poland
  • UCK im. prof. K. Gibińskiego Katowice, Poland
  • Maria Sklodowska-Curie National Research Institute of Oncology / Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy Warsaw, Poland
View Trial Details
Active, Not Recruiting

Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

NCT03386513

Conditions
Blastic Plasmacytoid Dendritic Cell Neoplasm, Bone Marrow Diseases, Disease Attributes, +25 more
Locations
  • Banner Health MD Anderson Cancer Center Gilbert, Arizona, United States
  • City of Hope Medical Center Duarte, California, United States
  • UCLA Los Angeles, California, United States
  • Stanford Stanford, California, United States
View all 28 locations
View Trial Details
Active, Not Recruiting

A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS)

NCT03385226

Conditions
Cutaneous T Cell Lymphoma, Disease Attributes, Hemic and Lymphatic Diseases, +16 more
Locations
  • University Hospital Birmingham Birmingham, United Kingdom
  • Velindre Cancer Centre Cardiff, United Kingdom
  • University Hospital Coventry Coventry, United Kingdom
  • Beatson West of Scotland Cancer Centre Glasgow, United Kingdom
View Trial Details

Related conditions